Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 7, pp. 585-594
Open Access | Times Cited: 2900

Showing 1-25 of 2900 citing articles:

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 16, pp. 1532-1546
Open Access | Times Cited: 2091
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Petra Mlčochová, Steven A. Kemp, Mahesh Shanker Dhar, et al.
Nature (2021) Vol. 599, Iss. 7883, pp. 114-119
Open Access | Times Cited: 1279
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof, Jeff Slezak, Heidi Fischer, et al.
The Lancet (2021) Vol. 398, Iss. 10309, pp. 1407-1416
Open Access | Times Cited: 1166
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. García-Beltrán, Kerri St. Denis, Angelique Hœlzemer, et al.
Cell (2022) Vol. 185, Iss. 3, pp. 457-466.e4
Open Access | Times Cited: 1020
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh, Jim McMenamin, J. R. Taylor, et al.
The Lancet (2021) Vol. 397, Iss. 10293, pp. 2461-2462
Open Access | Times Cited: 997
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 937
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda, Noa Dagan, Cyrille J. Cohen, et al.
The Lancet (2021) Vol. 398, Iss. 10316, pp. 2093-2100
Open Access | Times Cited: 860
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
Anika Singanayagam, Seran Hakki, Jake Dunning, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 2, pp. 183-195
Open Access | Times Cited: 753
Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 669
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
Sarah Cherian, Varsha Potdar, Santosh Jadhav, et al.
Microorganisms (2021) Vol. 9, Iss. 7, pp. 1542-1542
Open Access | Times Cited: 628
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
Victoria Hall, Sarah Foulkes, Ferdinando Insalata, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 13, pp. 1207-1220
Open Access | Times Cited: 621
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 19, pp. 1774-1785
Open Access | Times Cited: 571
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 553
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Emma Wall, Mary Wu, Ruth Harvey, et al.
The Lancet (2021) Vol. 397, Iss. 10292, pp. 2331-2333
Open Access | Times Cited: 549
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2127-2135
Open Access | Times Cited: 533
Homologous and Heterologous Covid-19 Booster Vaccinations
Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 11, pp. 1046-1057
Open Access | Times Cited: 532
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1161-1179
Open Access | Times Cited: 531
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
Katherine A. Twohig, Tommy Nyberg, Asad Zaidi, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 1, pp. 35-42
Open Access | Times Cited: 523
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
Michela Antonelli, Rose Penfold, Jordi Merino, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 1, pp. 43-55
Open Access | Times Cited: 466
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
David W. Eyre, Donald Taylor, M. B. Purver, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 8, pp. 744-756
Open Access | Times Cited: 438
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Shirley Collie, Jared Champion, Harry Moultrie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 5, pp. 494-496
Open Access | Times Cited: 438
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 415
Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients
Corine H. GeurtsvanKessel, Daryl Geers, Katharina S. Schmitz, et al.
Science Immunology (2022) Vol. 7, Iss. 69
Open Access | Times Cited: 404
Page 1 - Next Page

Scroll to top